I understand that for the present trial there may well be no clinical significance even if there had been borderline statistical significance. But if the intervention is in fact doing something, then a longer trial on earlier patients may indeed show clinical significance. It might even be that if they continue to follow these patients they will see a clinically significant effect. Or maybe there is some subgroup for which the drug works well.
My point is that I don't think this drug is yet dead.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.